"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04927611","Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm",,"Recruiting","No Results Available","Neuroendocrine Neoplasm","Procedure: Biopsy, open or laparoscopic surgery","Bioinformatics analysis of single-cell sequencing results|Model construction|Exploration of NEN organoid|Tumor microenvironment|Comparison of mechanism of NEN with PDAC","Fudan University|D1 Medical Technology (Shanghai) Co., Ltd, China","All","18 Years to 80 Years   (Adult, Older Adult)",,"200","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CSPAC-NEN-1","June 6, 2021","June 2022","December 2022","June 16, 2021",,"September 24, 2021","Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04927611"
2,"NCT05092009","Lung Cancer Organoids and Patient Derived Tumor Xenografts","Lung organoids","Recruiting","No Results Available","Lung Cancer","Other: Tissue and blood","Lung cancer organoids|Oncogenetic drivers|Tumor heterogeneity|Molecular biology|Treatment response|Xenografts|Therapeutic approaches|Developing biomarkers|Analysing blood","Maastricht Radiation Oncology","All","18 Years and older   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Lung Organoids","October 5, 2022","April 1, 2023","April 1, 2025","October 25, 2021",,"March 15, 2023","Zuyderland Medical Center, Heerlen, Netherlands|Maastricht Radiation Oncology (Maastro), Maastricht, Netherlands|MUMC+, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT05092009"
3,"NCT05038358","Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms","CRC-ORGA 2","Not yet recruiting","No Results Available","Development of an Organoid Collection From Fresh Human Primary Colonic Tumor Tissue",,"Percentage of viable organoids for 60 days of culture maintenance.","University Hospital, Grenoble","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021-A00793-38","September 30, 2021","June 30, 2026","September 30, 2026","September 9, 2021",,"September 9, 2021","University Hospital of Grenoble Alpes, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT05038358"
4,"NCT05577689","Novel Therapy Target in Metastatic Prostate Cancer","NTTPro","Not yet recruiting","No Results Available","Prostate Neoplasms","Other: Tissue","Multiple omics features|Organoids successfully generated from metastatic prostate cancer|Developing of biomarkers related to cancer metastasis and drug resistant|Animal models successfully generated from patient derived prostate cancer organoids|Response of the prostate cancer organoids to the selected anti-cancer compounds|Response of the PDOX models to the selected anti-cancer compounds","Fudan University","Male","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PCa-Organoid","March 1, 2023","November 1, 2025","May 1, 2026","October 13, 2022",,"October 13, 2022",,,"https://ClinicalTrials.gov/show/NCT05577689"
5,"NCT03890614","Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity","Organoid","Recruiting","No Results Available","Hematologic Malignancy","Other: Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates","Proportion of Live/Dead Myeloma Cells Using Bioprinting Technology|Tumor-Stroma Interactions|Number of Reduced Hematologic Malignant Myeloma Cells|Comparison of Cell Viability|Organoid Responses Compared to Clinical Response","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)",,"70","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00057612|Crowdcare Foundation|Pilot Fund|P30CA012197|WFBCCC26A19","May 16, 2019","April 2023","April 2023","March 26, 2019",,"November 3, 2022","Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03890614"
6,"NCT05290961","The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening",,"Recruiting","No Results Available","Ovarian Neoplasms",,"Progression-free Survival|Overall survival","Chongqing University Cancer Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CQGOG0202","March 9, 2022","December 31, 2024","December 31, 2024","March 22, 2022",,"March 22, 2022","Chongqing University Cancer Hospital, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT05290961"
7,"NCT04931394","Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer",,"Recruiting","No Results Available","Pancreatic Cancer","Other: Adjuvant chemotherapy guided by organoid drug sensitivity test","Disease free time|Overall survival time|1-year disease-free survival|The successful establishment rate of organoids|Concordance between drug sensitivity test results and patients' treatment response (descriptive statistics).|Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).","Changhai Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ChanghaiH-PP08","June 1, 2021","May 31, 2024","May 31, 2025","June 18, 2021",,"August 2, 2022","Changhai Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04931394"
8,"NCT03655015","Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer",,"Recruiting","No Results Available","Lung Neoplasm","Procedure: Lung Tumor Resection","To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.|Correlation of PDO and Circulating tumor cells (CTCs)","The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CTMS# 18-0056|HSC20180485H","October 16, 2018","November 2023","December 2024","August 31, 2018",,"January 25, 2023","UT Health San Antonio, M.D. Anderson Cancer Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03655015"
9,"NCT04768270","The Culture of Ovarian Cancer Organoids and Drug Screening",,"Recruiting","No Results Available","Ovarian Cancer","Other: no intervention","PFS|OS|ORR|DCR","Chongqing University Cancer Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CQGOG0201","April 12, 2022","December 31, 2023","December 31, 2024","February 24, 2021",,"April 26, 2022","Chongqing Cancer Hospital, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04768270"
10,"NCT05177432","Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer","QUEST","Recruiting","No Results Available","Breast Cancer","Device: QPOP","Objective response rate measured by RECIST 1.1 criteria to anti-cancer therapy selected by QPOP (prospective analysis).|Clinical benefit rate as determined by proportion of patients with complete response, partial response or stable disease as best response on RECIST 1.1 criteria (prospective analysis)|Progression-free survival of QPOP-guided therapy as measured by RECIST 1.1 criteria (prospective analysis)|Correlating QPOP prediction score of immediate past line of therapy and objective response rate to that therapy (retrospective correlative analysis)|Correlating objective response rate (ORR) measured by RECIST v1.1 of the tumor lesion biopsied for QPOP analyses with QPOP guided therapy (retrospective correlative analysis)","National University Hospital, Singapore","Female","21 Years to 99 Years   (Adult, Older Adult)","Phase 1","26","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BR02/03/21","December 6, 2021","January 3, 2025","December 31, 2025","January 4, 2022",,"February 28, 2022","National University Hospital Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT05177432"
11,"NCT05304741","The Culture of Advanced/Recurrent/Metastatic Colorectal Cancer Organoids and Drug Screening",,"Recruiting","No Results Available","Colorectal Cancer",,"Progression-free Survival|Overall Survival|Diagnostic Indicators","Chongqing University Cancer Hospital","All","18 Years to 70 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CQGOG0501","January 1, 2020","December 31, 2023","December 31, 2023","March 31, 2022",,"March 31, 2022","Chongqing University Cancer Hospital, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT05304741"
12,"NCT05404321","Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment","TRIPLEX","Recruiting","No Results Available","Triple Negative Breast Cancer|Organoid","Other: Establishment of ex vivo breast cancer organoid models","Rate of establishment of exploitable organoids tumor","Centre Francois Baclesse","Female","18 Years and older   (Adult, Older Adult)",,"163","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021-A02676-35","January 9, 2023","June 2026","December 2026","June 3, 2022",,"February 10, 2023","Centre François Baclesse, Caen, France",,"https://ClinicalTrials.gov/show/NCT05404321"
13,"NCT04931381","Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer",,"Recruiting","No Results Available","Advanced Pancreatic Cancer","Other: Chemotherapy guided by organoid drug sensitivity test","6-month disease control rate|Progression free time|Overall survival time|The successful establishment rate of organoids|Concordance between drug sensitivity test results and patients' treatment response (descriptive statistics).|Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).","Changhai Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ChanghaiH-PP09","June 1, 2021","May 31, 2024","May 31, 2025","June 18, 2021",,"August 2, 2022","Changhai Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04931381"
14,"NCT05007379","Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids","CARMA","Not yet recruiting","No Results Available","Breast Cancer",,"Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers|Antitumor activity of the CAR-macrophages compared to non-modified macrophages|Antitumor activity of the CAR-macrophages against organoids from early and advanced breast cancers patients","Centre Oscar Lambret|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 100 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CARMA-2101","September 1, 2021","September 1, 2023","September 1, 2023","August 16, 2021",,"August 16, 2021",,,"https://ClinicalTrials.gov/show/NCT05007379"
15,"NCT03952793","Organoids From Metastases of Prostate Cancer","OrMePro","Terminated","No Results Available","Prostatic Neoplasm","Other: extended biopsy","Success rate of establishment of the organoid culture|Drugs testing on organoid for cell viability|Cell Apoptosis Molecular and cellular mechanisms of drugs responses|Cell proliferation Molecular and cellular on mechanisms of drugs responses","Centre Antoine Lacassagne|Centre Méditerranéen de Médecine Moléculaire UMR_S-1065","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2018/63","December 4, 2019","October 25, 2021","October 25, 2021","May 16, 2019",,"November 1, 2021","Centre Antoine Lacassagne, Nice, France",,"https://ClinicalTrials.gov/show/NCT03952793"
16,"NCT05175326","Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs",,"Recruiting","No Results Available","Ovarian Cancer|Organoid",,"Prediction of the response to treatment by the patient-derived organoids","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","All","18 Years to 75 Years   (Adult, Older Adult)",,"64","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SYSEC-KY-KS-2021-294","November 1, 2021","June 1, 2022","November 1, 2022","January 3, 2022",,"January 3, 2022","The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05175326"
17,"NCT04371198","Patient-Derived Organoids for Rectal Cancer",,"Completed","No Results Available","Rectum Cancer","Other: Biopsy","fraction of biopsies that form spherical organoids.","Duke University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Pro00104561","September 18, 2020","August 18, 2022","August 18, 2022","May 1, 2020",,"August 22, 2022","Duke Cancer Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04371198"
18,"NCT03544255","Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues",,"Unknown status","No Results Available","Pancreatic Cancer|Pancreas Adenocarcinoma","Procedure: Biopsy","Number of organoids successfully generated from pancreatic cancer biopsies|Response of the pancreatic cancer organoids to the selected anti-cancer drugs","Ying Lv|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EFOP-01","May 1, 2018","December 1, 2020","June 1, 2021","June 1, 2018",,"January 7, 2020","Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT03544255"
19,"NCT04777604","Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Organoid",,"Not yet recruiting","No Results Available","Pancreas Cancer","Other: Organoid","Overall survival rate","Samsung Medical Center","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-12-106","March 1, 2021","January 7, 2025","January 7, 2026","March 2, 2021",,"March 2, 2021","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04777604"
20,"NCT05203549","Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric Cancer",,"Recruiting","No Results Available","Gastric Cancer","Procedure: Tumor biopsy","Establishment of patient-derived organoids|Correlation between results of the drug sensitivity tests in patient-derived organoid models and clinical outcomes","D1 Medical Technology (Shanghai) Co., Ltd, China|Shanghai Zhongshan Hospital","All","18 Years to 70 Years   (Adult, Older Adult)",,"250","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","D1med-GC1001","May 1, 2021","January 31, 2023","June 30, 2023","January 24, 2022",,"January 24, 2022","Zhongshan Hospital Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05203549"
21,"NCT04736043","Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid",,"Recruiting","No Results Available","Pancreatic Cancer Resectable","Other: Organoid","Overall survival rate","Samsung Medical Center","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-12-106-001","January 31, 2021","January 7, 2025","January 7, 2026","February 3, 2021",,"February 3, 2021","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04736043"
22,"NCT04996355","Organoids-on-a-chip for Colorectal Cancer and in Vitro Screening of Chemotherapeutic Drugs",,"Recruiting","No Results Available","Colorectal Neoplasms|Organoids","Other: comprehensive treatment after MDT discussion","The accuracy, specificity and sensitivity of organoids-on-chip for drug sreening","Peking University People's Hospital|Peking University","All","18 Years to 75 Years   (Adult, Older Adult)",,"52","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2021PHB148-001","May 31, 2021","May 30, 2022","May 30, 2024","August 9, 2021",,"August 18, 2021","Peking University People's Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04996355"
23,"NCT03990675","Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids",,"Unknown status","No Results Available","Pancreas Cancer","Procedure: FNA, FNB","Growth rate","Technical University of Munich","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pancreatic cancer organoids","December 1, 2018","August 1, 2021","August 1, 2022","June 19, 2019",,"June 19, 2019","2nd Medical Department, Klinikum rechts der Isar, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT03990675"
24,"NCT04342286","To Establish a Reproducible Organoid Culture Model With Human Kidney Cancer",,"Completed","No Results Available","Kidney Cancer","Genetic: Organoid culture","To establish a sustainable human kidney tumor 3D Matrigel culture system with a stable phenotype|The identicality of histopathological detail and genomic information of the kidney cancer organoid compared with the original primary tissue|The tumorigenicity ability of the kidney cancer organoid in nude mice","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CRE-2019.211","May 1, 2020","February 22, 2021","February 22, 2021","April 13, 2020",,"December 16, 2021","Prince of Wales Hospital, Shatin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04342286"
25,"NCT05401318","Tailoring Treatment in Colorectal Cancer","TargetCRC","Recruiting","No Results Available","Colorectal Neoplasms","Procedure: Tumor tissue sampling for organoid development","Clinical logistics pipeline for patient-derived organoid development success rate|Sensitivity report for chemotherapy and cellular immunotherapy by clinical evaluation|Induction of immunotherapy efficacy by chemotherapy in colorectal cancer, measured by advanced imaging analysis","University Hospital, Akershus|Oncosyne AS|Oslo University Hospital","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","350208 (REK)","March 28, 2022","March 28, 2025","January 1, 2027","June 2, 2022",,"June 2, 2022","Akershus University Hospital, Lørenskog, Viken, Norway",,"https://ClinicalTrials.gov/show/NCT05401318"
26,"NCT04755907","3D Bioprinted Models for Predicting Chemotherapy Response in Colorectal Cancer With/Without Liver Metastases",,"Recruiting","No Results Available","Colorectal Cancer|Colorectal Cancer Liver Metastasis","Procedure: surgical resection|Other: adjuvant chemotherapy|Other: neoadjuvant therapy","Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients.|Response of the colorectal cancer patients to neoadjuvant chemotherapy.","Peking Union Medical College Hospital|Peking University Cancer Hospital & Institute|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|China-Japan Friendship Hospital","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CRC-3D-Bioprint","March 1, 2021","December 31, 2022","December 31, 2023","February 16, 2021",,"July 19, 2022","Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|China-Japan Friendship Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04755907"
27,"NCT03979170","Patient-derived Organoids of Lung Cancer to Test Drug Response",,"Recruiting","No Results Available","Lung Cancer|Organoid","Procedure: Lung tumor resection","Patient-derived organoid establishment|Patient-derived organoid validation|Drug sensitivity|Prediction of the response to treatment by the patient-derived organoids","University Hospital, Geneva","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-02395","April 1, 2019","December 30, 2021","December 30, 2024","June 7, 2019",,"June 7, 2019","Geneva University Hospitals, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT03979170"
28,"NCT05267912","Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers","ORGANOTREAT","Recruiting","No Results Available","Advanced, Pretreated Solid Tumors","Procedure: Biopsy","ORGANOTREAT-01: Chemogram|ORGANOTREAT-02A: GMI|ORGANOTREAT-02B: PFS|ORGANOTREAT-02A and -02B: chemogram|ORGANOTREAT-01 and -02A: PFS|ORGANOTREAT-01 and -02B: GMI|ORGANOTREAT-01 and -02B: ORR|ORGANOTREAT-01 and -02B: duration of response|ORGANOTREAT-01 and -02B: DCR|ORGANOTREAT-01 and -02B: duration of disease control|ORGANOTREAT-01 and -02B: clinical benefit|ORGANOTREAT-01 and -02B: OS|ORGANOTREAT-01 and -02B: Number of chemogram-oriented treatment lines","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1919","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2021-A00939-32","January 19, 2022","January 2026","January 2027","March 7, 2022",,"March 7, 2022","Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT05267912"
29,"NCT04906733","Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients.",,"Recruiting","No Results Available","Colon Cancer|Organoids|Metastatic Cancer","Procedure: Tumor biopsy","Correlation of ex vivo sensitivity test on patient-derived organoid models with clinical outcomes","D1 Medical Technology (Shanghai) Co., Ltd, China|Fudan University","All","18 Years to 70 Years   (Adult, Older Adult)",,"80","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","D1med-ZL01","April 15, 2021","June 2023","December 2023","May 28, 2021",,"August 13, 2021","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT04906733/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04906733"
30,"NCT05442138","A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients",,"Not yet recruiting","No Results Available","Early Gastric Cancer|Tumor Organoids",,"Objective Response Rate|Tumor Regression Grading","Henan Cancer Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"54","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OneTar","August 2022","May 2023","June 2024","July 1, 2022",,"July 29, 2022",,,"https://ClinicalTrials.gov/show/NCT05442138"
31,"NCT05384184","Next Generation "" Pre-clinical Model for Colorectal Cancer Metastases and Hepatocellular Carcinomas (BORG)","BORG","Recruiting","No Results Available","Colorectal Cancer Metastases and Hepatocellular Carcinomas","Procedure: Tumor /metastases removal","Build the next generation biobank of liver-derived organoids|Biobank of liver-derived organoids efficiency|Evaluate the clinical relevance of the generated organoids","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RCAPHM19_0407","June 6, 2019","December 2022","December 2023","May 20, 2022",,"May 20, 2022","ap-HM hopital nord, Marseille, France",,"https://ClinicalTrials.gov/show/NCT05384184"
32,"NCT05024734","Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids",,"Recruiting","No Results Available","Bladder Cancer|Non-muscle Invasive","Drug: Epirubicin|Drug: Mitomycin|Drug: Gemcitabine|Drug: Docetaxel","Number of patients with successful drug selection|Side effects|Recurrence rate|QoL","University Hospital Inselspital, Berne|University of Bern|Hospital Centre Biel/Bienne","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SZB-URO-21-001","November 17, 2022","November 16, 2024","November 16, 2026","August 27, 2021",,"November 22, 2022","Roland Seiler, Biel, Switzerland",,"https://ClinicalTrials.gov/show/NCT05024734"
33,"NCT04555473","Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids","TAILOR","Recruiting","No Results Available","Organoids|Epithelial Ovarian Cancer","Procedure: Tumor biopsy","Reliability (yes/no) of HGSOC organoids obtained from PDS+adjuvant chemotherapy and NACT+IDS cases as a model for the patient's response to treatments|The genomic and phenotypic evolution of tumor cells in HGSOC organoids from PDS+ adjuvant chemotherapy and NACT+IDS patients undergoing relapse|Splicing dysregulation and splicing-targeting technologies as new potential therapeutic treatments to increase vulnerability of MYC-overexpressing HGSOCs","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Female","18 Years to 75 Years   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TAILOR","May 12, 2020","November 4, 2021","May 4, 2023","September 18, 2020",,"September 18, 2020","Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT04555473"
34,"NCT02436564","In Vitro Models of Liver and Pancreatic Cancer",,"Unknown status","No Results Available","Cholangiocarcinoma|Hepatocellular Carcinoma|Pancreatic Neoplasm","Genetic: Organoid in vitro culture","Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.|Proportion of tumour-derived organoids that are genetically identical to the source tumour.","Cambridge University Hospitals NHS Foundation Trust|The Gurdon Institute|Ann McLaren Laboratory of Regenerative Medicine","All","18 Years to 90 Years   (Adult, Older Adult)",,"75","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A093484","July 2015","September 2018",,"May 7, 2015",,"July 14, 2016","Addenbrooke's Hospital, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02436564"
35,"NCT05378048","Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors",,"Not yet recruiting","No Results Available","Organoids","Drug: PDO-guided treatment|Drug: standard of care","Tumor progression-free survival|the rate of overall survival|tumour response rates|rate of successful organoid culture and drug screen organoid culture|rate of serious adverse events","Chinese University of Hong Kong","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDO","July 4, 2022","July 3, 2025","July 3, 2025","May 17, 2022",,"May 17, 2022","Department of surgery , Prince of Wales Hospital, Hong Kong, N.t., Hong Kong",,"https://ClinicalTrials.gov/show/NCT05378048"
36,"NCT05669586","Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Non-small Cell Lung Cancer",,"Recruiting","No Results Available","Lung Cancer|Organoid|NSCLC","Drug: Antitumor therapy guided by organoid drug sensitivity test","Progression-free survival|Overall survival|Disease control rate|Changes in tumor volume shrinking|Prediction of the response to treatment by the patient-derived organoids|The rate of successful generation of lung cancer organoids","Affiliated Hospital of Jiangnan University","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","136286","February 1, 2023","May 31, 2024","May 31, 2026","January 3, 2023",,"February 3, 2023","Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05669586"
37,"NCT04611035","Q-GAIN (Using Qpop to Predict Treatment for GAstroIntestinal caNcer)",,"Recruiting","No Results Available","Gastrointestinal Cancer","Device: QPOP","Rates of radiological response|Percentage of patients with successful organoid generation for each different tumour type.|Efficacy of second-line therapy|Haematologic and non-haematologic toxicities","National University Hospital, Singapore","Female","21 Years to 99 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2019/00924","January 20, 2020","January 2023","January 2023","November 2, 2020",,"April 6, 2022","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04611035"
38,"NCT05652348","Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer","Hi-STEP1","Recruiting","No Results Available","Gastric Cancer|Colon Cancer|Peritoneal Carcinomatosis","Other: Establishment of organoid cultures and in vitro sensitivity testing","Evaluation of the sensitivity of the in vitro response of the organoid model to chemotherapeutic agents|Next generation sequencing of organoid cultures","Technische Universität Dresden|Deutsches Krebsforschungszentrum (DKFZ)","All","18 Years and older   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VTG-12","December 8, 2022","December 31, 2028","December 31, 2028","December 15, 2022",,"January 12, 2023","Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustv Carus Dresden, Dresden, Germany|University Hospital Heidelberg, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT05652348"
39,"NCT03577808","Organoids in Predicting Chemoradiation Sensitivity on Rectal Cancer",,"Unknown status","No Results Available","Organoids|Rectal Cancer|Chemoradiation","Other: Biopsy","Response of the rectal cancer organoids to irradiation and the same chemotherapy drugs as the corresponding patient.|Response of the rectal cancer patients to neoadjuvant chemoradiation.","Zhen Zhang|Fudan University","All","18 Years to 75 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FDRT-R008","August 17, 2018","August 1, 2020","November 1, 2020","July 5, 2018",,"August 20, 2018","Fudan University, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03577808"
40,"NCT03283527","Organoid Based Response Prediction in Esophageal Cancer","RARESTEM/Org","Unknown status","No Results Available","Organoid|Esophageal Cancer|Chemoradiation",,"Response prediction by EC-PDO|EC-PDO growth rate in-vivo|Stem cell characterization measured by the amount of CD24-/CD44+|Radio/Chemo-sensitivity/resistance; the effective dose 50% (ED50%) of CSCs enriched subpopulation will be compared with the ED50% esophageal cancer cell lines.|Clinical response: based on PET-CT (standard): complete, partial or no response|Disease free survival (DFS) in months in patients|Overall survival (OS) in months","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RARESTEM/Organoid","December 1, 2017","January 1, 2020","January 1, 2020","September 14, 2017",,"February 15, 2018","University Medical Center Groningen (UMCG), Groningen, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands",,"https://ClinicalTrials.gov/show/NCT03283527"
41,"NCT05734963","ORganoid GeneratioN Study for Cancer","ORIGINS","Recruiting","No Results Available","Cancer","Genetic: DNA sequencing, RNA gene expression analysis, molecular profiling","Establish patient-derived organoid (PDO) model for cancers|To collection contemporaneous biological samples from patients with cancer before and after surgery/biopsy, and again after any adjuvant therapy|To collect tumour tissue to facilitate evolutionary analysis with molecular analysis of multiple regions|Retrieval and analysis of archival primary tissue blocks for comparison where available|To establish co-culture tumour/stroma/immune cell models|To observe associations between molecular and clinicopathological data","Royal Marsden NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCR5396","April 4, 2022","April 12, 2031","April 12, 2031","February 21, 2023",,"February 21, 2023","The Royal Marsden Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05734963"
42,"NCT05196334","Pharmacotyping of Pancreatic Patient-derived Organoids",,"Recruiting","No Results Available","Pancreatic Cancer","Other: No intervention","Measurement of organoid's response to therapy|Validation of patient's response to therapy|Comparison between organoid's and patient's response","Herlev Hospital|Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pancreatic organoid protocol","July 1, 2021","June 30, 2023","December 31, 2024","January 19, 2022",,"March 1, 2023","Endoscopy Unit, Herlev Hospital, Herlev, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT05196334"
43,"NCT05317221","Developing Breast (Cancer) Organoids",,"Recruiting","No Results Available","Breast Cancer","Other: Not an extra intervention, tissue taken in routine practice will be used.","Living biobank|Organoids.","Maastricht Radiation Oncology|Maastricht University Medical Center|Maastricht University","Female","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Organoids Breast","September 1, 2022","April 1, 2028","May 1, 2028","April 7, 2022",,"March 16, 2023","Maastricht University Medical Center, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT05317221"
44,"NCT04279509","Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE)",,"Unknown status","No Results Available","Organoids|HNSCC|Epithelial Ovarian Cancer|Colorectal Cancer","Procedure: Tumor Core Biopsy|Procedure: Blood sampling","Overall radiological response rate|Correlation between patient genotype, tumor biomarkers and blood biomarkers with clinical outcome","National University Hospital, Singapore","All","21 Years to 99 Years   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MC01/01/19","May 29, 2019","May 2021","May 2022","February 21, 2020",,"September 9, 2020","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04279509"
45,"NCT05136014","Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model","OS-TUMOVASC","Enrolling by invitation","No Results Available","Lung Cancer|Lung Adenocarcinoma|EGFR Activating Mutation|KRAS Mutation-Related Tumors|Non Small Cell Lung Cancer","Other: Collection of surgical waste","Evaluation of the in vitro efficacy of osimertinib in a patient-derived organoid model alone or in combination|Identify non-responders to osimertinib in vitro","Central Hospital, Nancy, France|Institut de Cancérologie de Lorraine","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2021PI057","November 1, 2021","November 1, 2021","November 1, 2022","November 26, 2021",,"November 26, 2021","Seitlinger, Vandoeuvre-lès-Nancy, Lorraine, France",,"https://ClinicalTrials.gov/show/NCT05136014"
46,"NCT05351983","Patient-derived Organoids Drug Screen in Pancreatic Cancer",,"Recruiting","No Results Available","Pancreas Cancer|Pancreas Neoplasm|Pancreas Adenocarcinoma|Pancreatic Cancer|Pancreatic Neoplasms|Pancreatic Adenocarcinoma","Procedure: Surgical biopsy of tumoral tissue for organoid generation","Feasibility of the process|Safety of surgical biopsy and post-operative surgical complications.|Contamination rates|Chemosensitivity testing","Prof. Dr. med. Dres. h.c. Jan Schmidt, MME|Klinik Hirslanden, Zurich","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","HIRSLANDEN_PANC_001","September 22, 2022","June 2023","June 2023","April 28, 2022",,"October 25, 2022","Hirslanden Kliniks, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT05351983"
47,"NCT04450706","Functional Precision Oncology for Metastatic Breast Cancer","FORESEE","Recruiting","No Results Available","HER2-negative Breast Cancer","Other: Precision Medicine|Other: Physican Decision Making","Number of cases where clinically actionable outcomes were identified by the use of organoids and drug screening (functional precision oncology).|The time from patient sample collection to return of genomic characterization results.|The time from patient sample collection to return of drug screening results.|Performance: comparison between the number of clinically actionable outcomes identified by our functional genomic characterization and commercially available assays|Concordance: To assess the frequency with which our functional precision oncology testing identifies the same therapeutic vulnerabilities identified by commercial (gold standard) testing.","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI131027","February 16, 2021","August 2023","August 2025","June 29, 2020",,"June 10, 2022","Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04450706"
48,"NCT04859166","Prospective Primary Human Lungcancer Organoids to Predict Treatment Response","Organoids lung","Completed","No Results Available","Lung Cancer","Procedure: Organoids","Bio-banking|Frequency of organoid formation|Distribution|Proliferation|PDX models of lung cancer|Established PDX histologically|Established PDX genetically|Established PDX biologically|Test treatments|Test hypotheses|Generate cell lines","Maastricht Radiation Oncology","All","Child, Adult, Older Adult",,"10","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Organoids lung","November 15, 2017","October 1, 2022","October 1, 2022","April 26, 2021",,"March 15, 2023","Zuyderland Medical Center, Heerlen, Netherlands|Maastro, Maastricht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04859166"
49,"NCT05571956","Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy Samples",,"Recruiting","No Results Available","Pancreas Adenocarcinoma","Other: Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group","simultaneous establishment of pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts","Ajou University School of Medicine","All","20 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AJOUIRB-SMP-2020-222","July 1, 2020","February 28, 2024","February 28, 2025","October 7, 2022",,"October 10, 2022","Ajou University Hospital, Suwon, Gyeong Gi Do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05571956"
50,"NCT03925233","Breast Cancer Treatment Based on Organ-like Culture",,"Unknown status","No Results Available","Breast Cancer Organoids","Drug: Trastuzumab|Drug: Doxorubicin Hydrochloride|Drug: Epirubicin hydrochloride|Drug: Fluorouracil|Drug: Paclitaxel|Drug: Gemcitabine|Drug: Cisplatin|Drug: Recombinant Human Endostatin|Drug: Pirarubicin hydrochloride|Drug: Pyrrolidine|Drug: Ixabepilone|Drug: Tamoxifen citrate|Drug: Vinorelbine tartrate|Drug: Carboplatin|Drug: Methotrexate|Drug: Eribulin mesylate|Drug: Toremifene citrate|Drug: Anastrozole|Drug: Letrozole|Drug: Exemestane|Drug: Fulvestrant|Drug: Olaparib|Drug: Bevacizumab|Drug: Apatinib mesylate|Drug: Pattozumab|Drug: Capecitabine|Drug: Ear particles|Drug: Aidi Injection|Drug: Cyclophosphamide","Detection of cell viability|Detection of in vitro model drug sensitivity|Clinical efficacy assessment according to RECIST criteria","Xijing Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","KY20182079-F-1","January 2, 2019","December 15, 2021","December 15, 2021","April 24, 2019",,"April 24, 2019","JingSu, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT03925233"
51,"NCT03500068","Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.","OPT-1","Unknown status","No Results Available","Carcinoma, Pancreatic Ductal","Diagnostic Test: biopsies & blood analyses","Developing organoids from advanced pancreatic cancer patients that predict non response or response|Functional studies will be done with the patient derived organoids to find biomarkers that correlate with response in organoids and patients.","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2017-202","September 4, 2017","September 1, 2022","September 1, 2022","April 17, 2018",,"January 19, 2021","Academic Medical Center, Medical Oncology, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03500068"
52,"NCT05767931","Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer",,"Not yet recruiting","No Results Available","Invasive Breast Cancer",,"antitumor rate of multi-specific antibody in patient-derived organoids and PDX model","Peking University","Female","18 Years to 70 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BC-P32","March 6, 2023","November 6, 2024","March 6, 2025","March 14, 2023",,"March 14, 2023","Peking University Cancer Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05767931"
53,"NCT05352165","The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer",,"Not yet recruiting","No Results Available","Neoadjuvant Therapy","Drug: standard long-term therapy|Drug: FOLFOX and standard long-term radiotherapy|Drug: FOLFIRI and standard long-term radiotherapy|Drug: 5-FU and standard long-term radiotherapy|Drug: 5-FU and pembrolizumab and standard long-term radiotherapy|Drug: Other individualized treatments","Pathologic Complete Response|Postoperative complication|Tumor Regression Grading|Local recurrence|Distant metastasis|Treatment tolerance rate|R0 resection rate|anus-saving rate","Shanghai Minimally Invasive Surgery Center|Shanghai OneTar Biomedicine Co., Ltd.|Wuxi Branch of Ruijin Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","192","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MISC-WXXR-001","January 1, 2023","December 31, 2024","December 31, 2025","April 28, 2022",,"April 28, 2022",,,"https://ClinicalTrials.gov/show/NCT05352165"
54,"NCT05183425","Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis",,"Recruiting","No Results Available","Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases",,"The consistency of drug sensitivity|The establishment of PDO","Changhai Hospital","All","18 Years to 70 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CHCS-PDO","January 1, 2022","December 31, 2023","December 31, 2024","January 10, 2022",,"February 4, 2022","Department of Colorectal Surgery in Changhai Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05183425"
55,"NCT04261192","Establishment of Squamous Cell Organoids of the Head and Neck to Assess Their Response to Innovative Therapies","ORGAVADS","Recruiting","No Results Available","Head and Neck Cancer","Other: Constitution of tumor and blood samples","Rate of establishment of exploitable organoids tumor","Centre Francois Baclesse","All","18 Years and older   (Adult, Older Adult)",,"98","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-A03332-55","July 3, 2020","February 2023","February 2025","February 7, 2020",,"August 10, 2022","Centre François Baclesse, Caen, France|CHU de Caen, Caen, France",,"https://ClinicalTrials.gov/show/NCT04261192"
56,"NCT04561453","Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer",,"Recruiting","No Results Available","Biliary Tract Cancer|Cholangiocarcinoma|Gallbladder Cancer|Intrahepatic Cholangiocarcinoma|Perihilar Cholangiocarcinoma|Extrahepatic Cholangiocarcinoma|Hilar Cholangiocarcinoma|Distal Bile Duct Cancer","Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring","Success Rate of Organoid Culture and Drug Screen|Success Rate of Obtaining circulating tumor DNA (ctDNA) quantification and Ability to assess change in ctDNA levels across those time points|Physician-Adjudicated Utility of Profiling Test Results - Post-Adjuvant Therapy|Prospective Concordance of Organoid Drug Screen Results and In Vivo Drug Activity|Predictive Value of circulating tumor DNA (ctDNA) for Recurrence|Concordance of Organoid Drug Screen Results with Next Generation Sequencing (NGS)-Predicted Drug Sensitivities|Physician-Adjudicated Utility of Profiling Test Results - At Time of Recurrence|Predictive Value of circulating tumor DNA (ctDNA) for Response to Medical Therapy","University of Washington|Natera, Inc.|SEngine Precision Medicine, Inc.","All","18 Years and older   (Adult, Older Adult)",,"20","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RG1121019|STUDY00010051","July 8, 2020","July 31, 2023","July 1, 2025","September 23, 2020",,"January 25, 2023","University of Illinois at Chicago, Chicago, Illinois, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04561453"
57,"NCT04842006","Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer","SYNCOPE","Recruiting","No Results Available","Colorectal Cancer","Drug: Total neoadjuvant therapy (TNT)|Diagnostic Test: Minimal residual disease (MRD)|Radiation: Long radiation therapy","Recurrence-free survival|Postoperative ctDNA|CRC-specific survival|overall survival|number of surgically resected patients resected patients|R0-resection rate|local recurrence rate|complete pathological response response rate|complete clinical response rate|total uptake of chemotherapy|adverse effects of surgery effects of surgery|adverse effects of chemotherapy|Treatment response by patient-derived organoid (PDO) therapy response","Helsinki University Central Hospital","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","93","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUS/155/2021","December 20, 2021","August 31, 2028","December 31, 2031","April 12, 2021",,"March 6, 2023","Helsinki University Central Hospital, Helsinki, Uusimaa, Finland|Tampere University Hospital, Tampere, Finland",,"https://ClinicalTrials.gov/show/NCT04842006"
58,"NCT05725200","Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","EVIDENT","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Alectinib|Drug: Cetuximab|Drug: Crizotinib|Drug: Dasatinib|Drug: Everolimus|Drug: Encorafenib|Drug: Gemcitabine|Drug: Idelalisib|Drug: Larotrectinib|Drug: Methotrexate|Drug: Palbociclib|Drug: Panobinostat|Drug: Pembrolizumab|Drug: Petrozumab|Drug: Trastuzumab|Drug: Talazoparib|Drug: Venetoclax","Pre-Screening: Obtain a combined pharmacogenomic profile which can be used to provide a MTB-nominated treatment|Main Study: To evaluate the anti-tumor activity, measured as objective response rate (ORR) of MTB-nominated therapies with drugs not approved or implemented in standard of care (SOC) for treatment of mCRC.|Pre-Screening: To obtain a full combined pharmacogenomic profile from a tumor biopsy that is eligible for treatment decisions in a standard oncology practice.|Main Study: Progression-free survival (PFS) and duration of response (DOR)|Main Study: Overall survival (OS)|Main Study: Safety and tolerability of the different MTB-nominated treatments|Main Study: Objective response of an MTB-nominated anti-cancer therapy compared to objective response to the prior line(s) SOC treatment.|Main Study: Efficacy of MTB-nominated anti-cancer therapy compared to the efficacy of prior lines SOC treatment.|Main study: Objective response of an MTB-nominated anti-cancer therapy compared to objective response to the next line(s) SOC treatment.|Main study: Efficacy of an MTB-nominated anti-cancer therapy compared to the efficacy achieved by the next line(s) of SOC treatment.|Main study: Patient-reported outcome measures.","Oslo University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EVIDENT","September 27, 2022","December 31, 2038","December 31, 2040","February 13, 2023",,"February 21, 2023","Oslo University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT05725200"
59,"NCT05351398","The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer",,"Not yet recruiting","No Results Available","Advanced Gastric Carcinoma","Drug: PDO group|Drug: Traditional group","Objective Response Rate|postoperative complication|postoperative tumor regression grading|3-year recurrence rate|chemotherapy tolerance and adverse reaction rate|R0 resection rate","Shanghai Minimally Invasive Surgery Center|Wuxi Branch of Ruijin Hospital|Shanghai OneTar Biomedicine Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)",,"54","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MISC-WXXR-002","April 2022","June 2023","December 2023","April 28, 2022",,"April 28, 2022","Shanghai Ruijin Hospttal, Shanghai, Sahnghai, China",,"https://ClinicalTrials.gov/show/NCT05351398"
60,"NCT03821870","Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity","TIP","Recruiting","No Results Available","Metastatic Pancreatic Cancer","Diagnostic Test: Inditreat|Drug: Experimental drug","Predictive value of in-vitro testing|Feasibility of selecting second-line therapy based on pre-treatment biopsies as measured by treatment response (RESIST 1.1 criteria)|Feasibility of selecting second-line therapy based on pre-treatment biopsies as measured by progression free survival (PFS)","Vejle Hospital","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TIP","February 25, 2019","December 31, 2021","December 2023","January 30, 2019",,"April 27, 2022","Departmen of Oncology, Vejle Hospital, Vejle, Denmark",,"https://ClinicalTrials.gov/show/NCT03821870"
61,"NCT04865315","A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors","HiLoGlio","Active, not recruiting","No Results Available","Low-grade Glioma|High Grade Glioma",,"Phenotypic, genetic, epigenetic proteomic and transcriptomic profile of the LGG/HGG PDOs","Maastricht Radiation Oncology|Maastricht University Medical Center|Zuyderland Medisch Centrum|Ziekenhuis Oost-Limburg","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","HiLoGlio Organoid Study","May 1, 2022","December 2024","December 2024","April 29, 2021",,"August 24, 2022","Maastricht Radiation Oncology, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT04865315"
62,"NCT04278326","Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments","ORGANOIDES","Recruiting","No Results Available","HPV Infection|Vaginal Cancer|Cervical Dysplasia|Cervical Cancer","Procedure: Vaginal Biopsy","To develop a 3D vaginal organoid culture model.|Inhibition of HPV molecular therapeutics using oligonucleotide, and siRNA (small interfering RNA)","Centre Hospitalier Régional d'Orléans|CNRS - Pr Chantal PICHON","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CHRO-2019-08","March 6, 2020","April 2024","April 2024","February 20, 2020",,"April 6, 2022","CHR Orléans, Orléans, France",,"https://ClinicalTrials.gov/show/NCT04278326"
63,"NCT03874559","Exosomes in Rectal Cancer",,"Unknown status","No Results Available","Rectal Cancer","Diagnostic Test: Blood Draw","Exosomal Biomarkers Assessment|Exosomal Expression|Exosomal Functionality Assessment","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Protocol IIT-RE-0","February 13, 2018","February 1, 2021","February 1, 2022","March 14, 2019",,"March 14, 2019","University of Kansas Medical Center/ Cancer Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03874559"
64,"NCT03140592","Pancreatic Cancer Models Developed From EUS Guided Biopsy Tissue",,"Unknown status","No Results Available","Pancreatic Cancer|Pancreatic Adenocarcinoma|Pancreatic Cyst","Procedure: Biopsy","Successful generation of pancreatic organoids","Stony Brook University","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRBNet # 618834","January 14, 2015","January 2023","January 2023","May 4, 2017",,"March 19, 2021","Stony Brook University, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT03140592"
65,"NCT05464082","Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC","TOWARDS-II","Suspended","No Results Available","Breast Cancer Recurrent","Other: Functional Precision Oncology","Proportion of cases where clinically actionable therapies were identified by FPO.|Compare the recurrence rates between patients whose tumors successfully engrafted in mice (PDX+) vs. not (PDX-)|Correlation between tumor engraftment (PDX+/-) and relapse-free survival, overall survival, and response to preoperative chemotherapy and treatment response as assessed on the Residual Cancer Burden scale|Proportion of cases where any type of patient derived models are successfully generated and clinically actionable therapies are identified by functional precision oncology.|Correlation between MHCII Immune Activation Score (high vs. low and as a continuous variable) and tumor engraftment (PDX+/-) and clinical outcomes (relapse-free and overall survival).|Correlation between methylated ctDNA measurements as assessed using the MethylPatch assay pretreatment, pre- and post surgery, with PDX engraftment data (+/-) and clinical outcomes (relapse-free and overall survival)|frequency with which therapeutic responses in PDX, PDxO, and/or PDO align with the clinical, radiographic, and pathologic responses observed in the matched patient|determine the feasibility of returning FPO results to inform the selection of 2nd line therapy after recurrence|Calculate PFS ratios of 2nd line FPO-informed: 1st line ""uninformed"" therapy as a preliminary measure of efficacy","University of Utah|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI153239","January 6, 2023","September 30, 2025","September 30, 2027","July 19, 2022",,"January 10, 2023","Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05464082"
66,"NCT04770974","Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic",,"Recruiting","No Results Available","Urothelial Carcinoma|Bladder Cancer|Urothelial Neoplasm|Urothelial Carcinoma Bladder|Urothelial Carcinoma in Situ","Other: Biomarkers and proteomics","Metabolomic|Spectroscopy|Progression|Response to treatments|Survival|Transcriptomic","University of Florence|University of Milano Bicocca|Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy|Careggi Hospital","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17852_bio","December 10, 2020","December 7, 2022","December 7, 2022","February 25, 2021",,"May 9, 2022","Careggi Hospital, Florence, Tuscany, Italy",,"https://ClinicalTrials.gov/show/NCT04770974"
67,"NCT03778814","TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors",,"Recruiting","No Results Available","Nonsmall Cell Lung Cancer|Solid Tumor, Adult","Biological: TCR-T cells","Number of Patients with Dose Limiting Toxicity|Percent of Patients with best response as either complete remission or partial remission","Second Affiliated Hospital of Guangzhou Medical University|Tcell Immune (Guangzhou) Science and Technology Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZZTCRT-006","December 1, 2018","December 30, 2025","December 30, 2033","December 19, 2018",,"February 14, 2023","The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03778814"
68,"NCT04826913","High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization","TUMOVASC","Not yet recruiting","No Results Available","NSCLC","Device: Organoids","Testing of anti-cancer drugs","University Hospital, Strasbourg, France","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","8036","April 2021","April 2021","April 2024","April 1, 2021",,"April 1, 2021","Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT04826913"
69,"NCT04968990","Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation",,"Recruiting","No Results Available","Wilms Tumor","Device: Proton Beam Radiation (PBRT)|Drug: DD-4A Chemotherapy Regimen|Procedure: Complete Surgical Resection|Procedure: Surgical Resection|Procedure: Partial Nephrectomy","Half circumference at 3 year|Half circumference at 5 year|Half circumference at 7 year|Half circumference at 10 year|Local control rate in a partially radiated kidney","St. Jude Children's Research Hospital","All","Child, Adult, Older Adult","Phase 2","95","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SJWT21","August 19, 2021","December 2026","December 2036","July 20, 2021",,"September 6, 2022","St.Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04968990"
70,"NCT04703244","Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer",,"Recruiting","No Results Available","Breast Cancer|Residual","Procedure: chemotherapy or endocrine therapy for breast cancer","Generate patient derived xenografts (PDX) and organoids from breast cancer patients with residual disease after neoadjuvant therapy|Utilize patient derived xenografts (PDX) models to study new drugs/drug combinations|Utilize patient derived xenografts (PDX) models to identify mechanisms of treatment resistance|Correlate the association between Cell Free DNA (cfDNA), Circulating Tumor Cells (CTCs) and circulating immune cell subpopulations (as measured by CyTOF) with residual cancer burden|Correlate the association between Cell Free DNA (cfDNA) with residual cancer burden|Correlate the association between Circulating Tumor Cells (CTCs) with residual cancer burden|Correlate the association between circulating immune cell subpopulations (as measured by Cytometry by time-of-flight (CyTOF) with residual cancer burden|Generate autologous co-culture systems of peripheral blood immune cells and breast cancer tumor cells to study the endogenous antitumor immune response","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MC1933","January 13, 2021","January 15, 2041","January 15, 2042","January 11, 2021",,"February 14, 2023","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04703244"
71,"NCT02732860","Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host","REFLECT","Recruiting","No Results Available","Colorectal Neoplasms|Colorectal Cancer|Breast Cancer|Breast Neoplasms|Ovarian Cancer|Ovarian Neoplasm","Other: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures","Measure of drug sensitive pPDX to a panel of drugs as a predictor of clinical response in matched host|Rate of results reporting|Rate of pPDX engraftment|Comparison of actionable alterations identified in clinical and pPDX samples|Number of patients with molecular abnormalities in pPDX as identified via NGS eliciting clinical responses while receiving matched treatments.|Correlation between pPDX and organoid drug sensitivities","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REFLECT-001","December 2015","November 2023","November 2023","April 11, 2016",,"April 14, 2022","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02732860"
72,"NCT04504747","Real Time Molecular Analysis of Breast Cancer Receiving Neo-adjuvant Chemotherapy","NEO-R","Recruiting","No Results Available","Breast Cancer Female","Other: molecular analysis of blood and tumor","Identify robust candidates - ""innate, ""acquired stable"" and/or reversible""|public repertoire of whole transcriptome and targeted-NGS|Identify molecular signatures associated with response to NAC|Establish PDO samples exposed to NAC|Evaluation of CTCs features","Institut Paoli-Calmettes","Female","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NEO-R-IPC 2019-041","November 3, 2022","January 2025","January 2030","August 7, 2020",,"March 2, 2023","Institut Paoli-Calmettes, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04504747"
73,"NCT04727632","[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial",,"Recruiting","No Results Available","Estrogen Receptor Positive Breast Cancer","Drug: [18F]Fluoroestradiol (FES) PET/CT","Number of patients on the FORESEE trial refractory to all combinatorial hormonal therapies that are recruited and imaged with FES-PET/CT prior to switching to non-hormonal therapeutic agents|Rate of concordance between FES-PET/CT imaging (positive or negative uptake) and ER status from tumor biopsy|Rate of concordance between positive FES-PET/CT scan and response to hormonal therapies from drug profiling results using patient-derived organoid models","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HCI140278","March 31, 2021","April 30, 2023","April 30, 2025","January 27, 2021",,"April 22, 2022","Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04727632"
74,"NCT05381038","Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI",,"Not yet recruiting","No Results Available","Solid Tumor|Gastrointestinal Cancer|Breast Cancer","Device: QPOP|Device: CURATE.AI|Drug: Azacitidine + docetaxel|Drug: Azacitidine + paclitaxel|Drug: Azacitidine + irinotecan","QPOP applicability: percentage of participants with successful application of QPOP drug selection.|CURATE.AI applicability: percentage of participants in whom the investigators successfully apply CURATE.AI profile.|Physician adherence: percentage of QPOP recommended drug combinations that were used by the co-investigator.|Patient adherence: percentage of participants who always adhered to the prescribed dose whenever they took their medication, as measured by the standardised pharmacovigilance protocol.|Timely delivery of CURATE.AI recommendations to the clinician: percentage of CURATE.AI recommendations provided in time for the next chemotherapy cycle, across all participants and cycles.|CURATE.AI relevance: percentage of dosing events across all participants and cycles in which CURATE.AI recommendation is considered in the clinical decision-making process|Physician adherence: percentage of CURATE.AI recommended doses that were used by the co-investigator.|Clinically significant dose changes","National University Hospital, Singapore|The N.1 Institute for Health (N.1)|Cancer Science Institute of Singapore","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021/01159","June 2022","October 4, 2026","April 4, 2027","May 19, 2022",,"May 19, 2022","National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT05381038"
75,"NCT05720676","Clinical, Histological and In-depth Molecular Characterization as Well as Experimental Models of Liver Metastasis From Patients With Breast Cancer in Order to Identify New Potential Treatment Avenues.","OLiver Pro","Not yet recruiting","No Results Available","Breast Cancer|Liver Metastases",,"To characterize the tumour cells and their microenvironment in the liver metastases at the transcriptomic and protein single-cell level.|To determine the levels and patterns of immune infiltrates in liver metastases from BC patients|To identify biological features associated with the histopathological growth patterns in liver metastases.|To create patient-derived xenografts (PDX) and organoids (PDO) from liver metastases isolated from patients with BC|To perform a histopathological and molecular comparison of liver metastases, PDX and PDO isolated from the same patient.|To investigate the histopathological growth patterns of liver metastases using intra-vital imaging of these metastases in PDX.|To use PDX and PDO to evaluate the efficacy of various treatments.","KU Leuven|Jules Bordet Institute|Erasme University Hospital|GZA Ziekenhuizen Campus Sint-Augustinus","Female","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","S-64813","March 2023","March 2025","March 2025","February 9, 2023",,"February 9, 2023","Sophia Leduc, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT05720676"
76,"NCT04820179","Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer",,"Recruiting","No Results Available","Pancreatic Cancer|Metastatic Pancreatic Cancer","Drug: Cabozantinib + Atezolizumab","Overall Response Rate or Stable Disease|Adverse Event|Toxicities|Disease Control Rate|Survival|Immune System Effects|Tumor Response|T2 Signal","University of Arizona","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2108097176","October 12, 2021","March 1, 2023","March 1, 2023","March 29, 2021",,"December 16, 2022","University of Arizona Cancer Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04820179"
77,"NCT04220242","Future of Colorectal Cancer Surgery","FOCCuS1","Unknown status","No Results Available","Colorectal Cancer|Surgery","Other: Video recordings with analysis thereafter applied|Other: Examination of microsections of tissue excised for the purposes of cancer resection|Other: Cancer organoid development and testing","Video recordings of Colorectal Cancer.|Analysis of video recordings|Biophysics visualisation software development|Biophysics model training|Validation of predictive accuracy biophysics-visualisation model|Coefficients of Variation|Microscopic Map of intratumoral fluorophore accumulation|Realtime delineation display of tumour area including margins","Mater Misericordiae University Hospital|Royal College of Surgeons, Ireland|IBM Research In Ireland","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","DT 2018 0240","December 30, 2019","December 1, 2022","March 1, 2023","January 7, 2020",,"January 7, 2020","Mater Misericordiae University Hospital, Dublin, Other (Non U.s.), Ireland",,"https://ClinicalTrials.gov/show/NCT04220242"
78,"NCT04281355","Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy","INDAX","Withdrawn","No Results Available","Breast Cancer","Procedure: Omission of axillary lymph node dissection|Radiation: Omission of regional irradiation","iDFS","Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EUBREAST-2 INDAX","January 1, 2021","December 31, 2025","December 31, 2029","February 24, 2020",,"February 25, 2021",,,"https://ClinicalTrials.gov/show/NCT04281355"
79,"NCT03544047","Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model",,"Unknown status","No Results Available","Organoid","Drug: Paclitaxel","Overall Response rates (ORR)|Surgical excision rate|Pathologic complete respons (pCR) rate|Disease-free survival (DFS)","Peking Union Medical College","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCC201804007","January 1, 2019","July 1, 2020","July 1, 2020","June 1, 2018",,"December 11, 2018","National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03544047"
80,"NCT05429684","Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer",,"Recruiting","No Results Available","HER2+ Breast Cancer","Drug: Trastuzumab|Drug: Pertuzumab|Drug: Nab paclitaxel|Drug: Pyrotinib|Drug: Capecitabine|Drug: T-DM1|Drug: Everolimus|Drug: CDK4/6 inhibitor|Drug: AI|Drug: Anti-PD-1 monoclonal antibody","ORR|PDO model inhibition rate|PFS1","First Affiliated Hospital Xi'an Jiaotong University","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XJTU1AF-CRF-2020-006","January 1, 2021","February 28, 2024","February 28, 2024","June 23, 2022",,"June 23, 2022","The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Jin Yang, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT05429684"
81,"NCT03300102","Acceptability and Feasibility Study of Patient-specific 'Tumouroids' as Personalised Treatment Screening Tools","Tumouroids","Completed","No Results Available","Cancer","Other: Questionnaires, interviews and or tissue donation","Acceptability|Feasibility : Number of tumour tissue samples collected|Feasibility : Gross morphology, weight and size of each sample|Feasibility : Cell count after isolation|Feasibility: Cell growth method and time|Feasibility: Drug concentrations tested|Feasibility: Duration of drug exposure|Feasibility: Drug challenge response","University College, London","All","18 Years and older   (Adult, Older Adult)",,"19","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17/0351","January 10, 2018","August 1, 2018","December 31, 2018","October 3, 2017",,"January 24, 2019","Surgical & Interventional Trials Unit, London, United Kingdom|Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03300102"
82,"NCT05242237","Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform",,"Recruiting","No Results Available","Hepatocellular Carcinoma|Circulating Tumor Cell|Whole Genome Sequencing",,"Time to progression or death (months)","The Second Affiliated Hospital of Chongqing Medical University|Cellomics International Limited","All","18 Years to 70 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HCC-CTC","December 1, 2021","January 31, 2024","January 31, 2024","February 16, 2022",,"February 16, 2022","the second affiliated hospital of Chongqing Medical University, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT05242237"
83,"NCT05338073","KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models",,"Recruiting","No Results Available","Cancer|Predictive Cancer Model|Effects of Chemotherapy","Diagnostic Test: Known 3Dx Test","Drug treatment response|Predictive of tumor response","Known Medicine, Inc.|M.D. Anderson Cancer Center|Duke Cancer Institute","All","18 Years and older   (Adult, Older Adult)",,"2000","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","KM-20-001","January 12, 2021","January 31, 2025","January 31, 2026","April 20, 2022",,"January 10, 2023","Mayo Clinic, Rochester, Minnesota, United States|Duke Cancer Institute, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05338073"
84,"NCT03453307","Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients",,"Unknown status","No Results Available","NSCLC",,"Correlation of ex vivo sensitivity test on patient derived organoid models","K2 Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","K2OLC-001","January 30, 2018","July 30, 2020","July 30, 2021","March 5, 2018",,"March 5, 2018","People's Hospital of Hebei Province, Shijiazhuang, Hebei, China",,"https://ClinicalTrials.gov/show/NCT03453307"
85,"NCT05400239","SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome",,"Not yet recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer",,"Successful Organoids|Sensitivity|Treatment Outcome","Guy's and St Thomas' NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SOTO Study 305689","May 2022","May 2023","May 2023","June 1, 2022",,"June 1, 2022",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT05400239/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT05400239"
86,"NCT03429816","OPPOSITE: Outcome Prediction Of Systemic Treatment in Esophagogastric Carcinoma","OPPOSITE","Active, not recruiting","No Results Available","Gastric Neoplasm|Gastroesophageal Junction Adenocarcinoma|Esophageal Adenocarcinoma|Gastric Adenocarcinoma|Esophageal Neoplasms","Procedure: Biopsy","Aim 1: Correlation of in-vitro response in the organoid model with histological regression in the resected tumor|Aim 2: Correlation of molecular subtypes with histological response after neoadjuvant therapy in patients|Aim 1: Correlation of in-vitro response in the organoid model with relapse-free survival|Aim 2: Correlation of molecular subtypes with relapse-free survival","University Hospital Heidelberg|University Hospital Dresden|German Cancer Research Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OPPOSITE","April 15, 2018","November 1, 2021","August 2022","February 12, 2018",,"February 23, 2022","University Hospital Dresden, Dresden, Germany|National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT03429816"
87,"NCT04281641","Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer","PHC-BC","Recruiting","No Results Available","HER2-positive Breast Cancer","Diagnostic Test: TCHP","Percent Change in Standardized Uptake Value (SUV) on Positron Emission Tomography and Change in Gene Expression With Response|Pathologic complete response in the breast and lymph nodes (ypT0/Tis ypN0)|Invasive disease-free survival (iDFS) (excluding Second Primary Non-Breast Cancer [SPNBC])|iDFS (including SPNBC)|Overall survival (OS)","Fudan University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","94","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SCHBCC-NO28","April 21, 2020","April 30, 2025","April 30, 2030","February 24, 2020",,"May 4, 2020","Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04281641"
88,"NCT05375266","Immune Biomarker Study for Head and Neck Cancer","ImmunBio-KHT","Recruiting","No Results Available","Head and Neck Cancer|Oral Cavity Cancer|Oropharyngeal Cancer|Hypopharyngeal Cancer|Laryngeal Cancer","Other: Sampling","Observation of changes in an established immune matrix (intratumoral and systemic) of responding/non-responding patients at certain points in time in the course of treatment|Longitudinal immunophenotyping of the patients: Detection of about 30 distinct immune cell (sub)types together with their activation markers during study period|Analysis of cytokines in peripheral blood and their change at certain points in the course of treatment|Determination of transcription processes in the immune cells at certain points in the course of treatment to extend the prognostic immune signature|Analysis of patient's metabolic state|Analysis of patient's microbiomic state by examination of saliva, tumor and stool","University of Erlangen-Nürnberg Medical School|University Hospital Erlangen|University Hospital Regensburg|University Hospital Augsburg","All","18 Years and older   (Adult, Older Adult)",,"1100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","12-384-B","May 16, 2022","March 31, 2026","March 31, 2027","May 16, 2022",,"January 25, 2023","ENT - Head and Neck Surgery Department, Erlangen, Bavaria, Germany|Maxillo-Facial-Surgery Department, Erlangen, Bavaria, Germany|Radiation Oncology Department, Erlangen, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT05375266"
89,"NCT04655573","A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer",,"Recruiting","No Results Available","Advanced Breast Cancer","Procedure: Breast Cancer Tumor Resection","The proportion of patients with successful generation of PDMO from the patient's biopsy|Association between specific chemotherapy sensitivity in PDMO to clinical outcome of patient","Duke University","All","18 Years and older   (Adult, Older Adult)",,"15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00107118","April 7, 2022","October 1, 2023","October 1, 2024","December 7, 2020",,"July 15, 2022","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04655573"
90,"NCT05134779","De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You","DIGNITY","Recruiting","No Results Available","Triple Negative Breast Cancer","Procedure: Live Biobank","establish a live biobank for triple negative breast cancer patients|assess immune relevant genes from tumor biopsies","Weill Medical College of Cornell University","Female","18 Years to 90 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","21-06023682","January 12, 2022","December 31, 2027","December 31, 2028","November 26, 2021",,"March 29, 2022","Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York, United States|New York Presbyterian Hospital - Queens, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05134779"
91,"NCT05772741","Grafts of GSCs Into Brain Organoids for Testing Anti-invasion Drugs","2253","Recruiting","No Results Available","Glioblastoma|Glioma, Malignant","Other: Biological sample collection","Invasion|Gene assessment","Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Catholic University of the Sacred Heart|Istituto Superiore di Sanità|Heinrich-Heine University, Duesseldorf","All","18 Years and older   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2253","December 3, 2018","December 31, 2023","December 31, 2023","March 16, 2023",,"March 16, 2023","Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT05772741"
92,"NCT03081988","Prediction Model of Response for CCRT in Esophageal Cancer",,"Recruiting","No Results Available","Esophageal Cancer","Other: chemoradiotherapy","Prediction model for CCRT response based on clinical and genetic molecular factors|banking of remained human material for post genetic & molecular study|circulating preditction marker for CCRT response and prognosis|tissue prediction marker for CCRT response and prognosis|in-vitro prediction of CCRT using primary esophageal cancer organoid","Kyungpook National University Hospital","All","40 Years to 80 Years   (Adult, Older Adult)",,"140","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2015R1D1A1A01059219","October 19, 2015","December 31, 2022","December 31, 2022","March 17, 2017",,"August 10, 2021","Kyungpook National University Medical Canter, Daegu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03081988"
93,"NCT01287468","Academia Sinica Investigator Award 2010",,"Unknown status","No Results Available","Breast Cancer",,,"Taipei Medical University WanFang Hospital","Female","20 Years and older   (Adult, Older Adult)",,"415","Other","Observational","Time Perspective: Prospective","99052","June 2010",,"December 2014","February 1, 2011",,"February 1, 2011","Taipei Medical University - WanFang Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01287468"
94,"NCT03896958","The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","PIONEER","Recruiting","No Results Available","Cancer, All Types|Cancer of Liver|Cancer of Stomach|Cancer of Head and Neck|Cancer of Rectum|Cancer of Kidney|Cancer of Esophagus|Cancer of Colon|Cancer Skin|Cancer of Cervix|Cancer, Metastatic|Cancer of Larynx|Cancer of Neck|Cancer of Lung|Cancer of Brain and Nervous System|Cancer of Vulva, Disseminated|Cancer of Pancreas|Sarcoma|GIST|Small-cell Lung Cancer|Adenocarcinoma Lung|Cancer of Prostate|Cancer, Advanced|Adrenal Cancer|Testicular Cancer|Uterine Cancer|Bronchoalveolar Cell Lung Cancer|Cancer Unknown Primary|Glioblastoma Multiforme|Oligodendroglioma|Breast Cancer|Renal Cell Carcinoma|Hepatocellular Carcinoma|Cholangiocarcinoma|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Cancer, Other|Cancer, Anal|Melanoma|Cancer, Bile Duct|Cancer, Bladder|Cancer Cords Vocal|Cancers Cell Neuroendocrine|Cancer Differentiated Poorly|Cancer, Anaplastic Thyroid",,"Return of research information|Assessment of benefit of return of research results|Assessment of benefit of return of research results by SpeciCare Outcome Monitor Board","SpeciCare|Georgia Institute of Technology|Predictive Oncology|University of Washington|Netnoids|Northeast Georgia Hospital System","All","1 Month to 99 Years   (Child, Adult, Older Adult)",,"1000","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MYCT001","March 21, 2019","March 12, 2024","March 12, 2024","April 1, 2019",,"December 4, 2020","Specicare, Gainesville, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03896958"
95,"NCT04714957","PITCHER (Peritoneal Carcinomatosis Heterogeneity)",,"Recruiting","No Results Available","Secondary Peritoneal Cancers|Colorectal Cancer|Ovarian Cancer","Other: construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.","genetic and epigenetic data available for 20 ""multiplets"" biospecimens (peritoneal carcinomatosis + healthy tissue + primary tumor + tissue from other tumor metastasis - when applicable and available- )","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Other|Time Perspective: Prospective","69HCL16_0672","September 1, 2020","September 2022","September 2027","January 20, 2021",,"January 20, 2021","Lyon SUD Hospital, Hospices Civils de Lyon, Lyon, France",,"https://ClinicalTrials.gov/show/NCT04714957"
96,"NCT04469556","Pancreatic Adenocarcinoma Signature Stratification for Treatment","PASS-01","Recruiting","No Results Available","Pancreatic Cancer Metastatic|Pancreatic Ductal Adenocarcinoma|Advanced Pancreatic Cancer","Drug: Folfirinox|Drug: Gemcitabine/nab-paclitaxel","Progression free survival(PFS) in mFFX and GA arms pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.|ORR by RECIST 1.1 and duration of response in patients receiving mFFX or GA|Overall survival (OS) associated with mFFX or GA profiles, signatures and pharmacotyping|GATA6 as a biomarker of response to mFFX or GA|• Concordance between organoid transcriptomic profiles (RNAseq) and patient transcriptomic profiles (descriptive statistics)|• Concordance between chemotherapy sensitivity signature predictions and response to first line treatment (descriptive statistics).|• Correlation of individual tumour cytokeratins (eg. CK5 and CK17 expression) with chemotherapy response and resistance|Cell free circulating tumor (ct) DNA analysis (including KRAS mutational status)|Cluster Tendency analysis using artificial neural networks and radiomic methods combined","University Health Network, Toronto|Johns Hopkins University|Cold Spring Harbor Laboratory|Ontario Institute for Cancer Research|Dana-Farber Cancer Institute|Memorial Sloan Kettering Cancer Center|Stand Up To Cancer","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PASS-01|CAPCR ID: 20-5105","October 14, 2020","September 2022","September 2023","July 14, 2020",,"April 13, 2022","Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Northwell Health, New Hyde Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|BC Cancer Agency Vancouver, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04469556"
97,"NCT02685046","Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy","ImPACCT","Terminated","No Results Available","Colonic Neoplasms","Drug: Imatinib","Effects of treatment on the mesenchymal gene expression profile|Extent of targeted inhibition of PDGFR and KIT phosphorylation in cancer cells|Correlation between plasma imatinib trough levels on day 14 and intratumoural concentration of imatinib in the resection specimen|Correlation between the extent of PDGFR and cKIT inhibition and systemic and intratumoural imatinib and CGP74588 concentration|Change in plasma CEA-concentrations|Change in plasma levels of circulating tumor DNA|Effects of imatinib on the ability of cancer cells to form in vitro 3D cell cultures (organoids)|Number of participants with treatment-related adverse events as assessed by CTCAEv4.02","UMC Utrecht|Meander Medical Center|Erasmus Medical Center|Hubrecht Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-TT-IMA-14|NL50620.041.15|2014-003965-11","April 2016","September 1, 2019","September 1, 2019","February 18, 2016",,"October 14, 2019","Meander Medical Center, Amersfoort, Utrecht, Netherlands|Diakonessenhuis, Utrecht, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02685046"
98,"NCT05696002","Advanced Pelvic Surgical Oncology Database - Prospective Observational Study",,"Recruiting","No Results Available","Rectal Cancer|Pelvic Cancer|Gynecologic Cancer|Colon Cancer",,"Cancer-specific survival|Overall survival|Post-operative complications|Quality of life (survey)","Glasgow Royal Infirmary","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Other","APSOD","January 14, 2023","January 1, 2028","January 1, 2030","January 25, 2023",,"January 25, 2023","Academic Department of Surgery, Glasgow Royal Infirmary, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05696002"
99,"NCT05332925","Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC","TUMORIN","Recruiting","No Results Available","Lung Cancer|NSCLC|NSCLC Stage IV","Drug: Standard of care immune checkpoint inhbitors","Feasibility of establishing 3D ex-vivo tumoroid model|Correlation of response in ex vivo tumoroids with clinical objective response","Jun Zhang, MD, PhD|Nilogen Oncosystems|University of Kansas Medical Center","All","18 Years to 110 Years   (Adult, Older Adult)",,"25","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","IIT-2021-Tumorin","July 21, 2022","January 2024","February 2024","April 18, 2022",,"September 22, 2022","The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States|The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT05332925"
100,"NCT01904916","CPCT-05 Biopsy Protocol Patient Selection",,"Terminated","No Results Available","Solid Tumors|Metastatic Disease","Procedure: Histological biopsy procedure","Percentage of screened patients allocated to trials based upon outcome of genetic screening effort.|Number and nature of (serious) adverse events of the performed histological biopsies.|Number of samples stored for future related research.|Number of samples with an adequate microRNA, (phospho)proteomic profiles and organoid cultures that allows biomarker discovery efforts. These profiles will be deposited in the CPCT database.","P.O. Witteveen|The Netherlands Cancer Institute|Erasmus Medical Center|UMC Utrecht","All","18 Years and older   (Adult, Older Adult)","Not Applicable","195","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NL.45677.041.13","January 2014","January 2016","March 2017","July 22, 2013",,"March 9, 2018","Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT01904916"
101,"NCT04723316","Tumour Characterisation to Guide Experimental Targeted Therapy - National",,"Recruiting","No Results Available","Cancer",,"To determine the number of patients matched to a trial of an experimental therapeutic agent based on molecular findings from ctDNA or tumour|Number of patients and cancer types with successful result obtained from ctDNA.|Turnaround times from date of patient consent to date of genomic tumour profiling report generation.|Number and range of molecular alterations found in blood (and/or tumour) of cancer patients referred to Experimental Cancer Medicine Centres.|Overall response rates of patients who commence on a trial of an experimental therapeutic agent (matched or unmatched) on the basis of molecular findings in this study).|Progression-free survival of patients who commence on a trial of an experimental therapeutic agent (matched or unmatched on the basis of molecular findings in this study).|Overall survival of patients who commence on a trial of an experimental therapeutic agent (matched or unmatched on the basis of molecular findings in this study).","The Christie NHS Foundation Trust","All","16 Years and older   (Child, Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CFTSp191","June 30, 2021","January 30, 2026","January 30, 2028","January 25, 2021",,"August 24, 2022","Queen's University Belfast, Belfast, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Cardiff University and Velindre Cancer Centre, Cardiff, United Kingdom|Western General Hospital Edinburgh Cancer Centre, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St.James's University Hospital, Leeds, United Kingdom|Leicester Cancer Research Centre, Leicester, United Kingdom|ICR & The Royal Marsden, London Borough of Sutton, United Kingdom|Royal Free Hospital, London, United Kingdom|Kings Health Partners, London, United Kingdom|Imperial College London, London, United Kingdom|UCL Cancer Institute, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Sheffield University Hospitals NHS Foundation Trust, Sheffield, United Kingdom|University Hospitals Southampton NHS Foundation Trust, Southampton, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04723316"
102,"NCT05251805","The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery",,"Not yet recruiting","No Results Available","Non Small Cell Lung Cancer","Procedure: Blood, bone marrow and lung tumor tissue collection","The occurrence of adverse events following costal bone marrow aspiration classified by Calvien Dindo|Measurement of the amount of HPSC's that can be obtained from costal bone marrow","Universitair Ziekenhuis Brussel","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UZB-DVH-2022-01","April 1, 2022","August 31, 2022","December 31, 2022","February 23, 2022",,"February 23, 2022",,,"https://ClinicalTrials.gov/show/NCT05251805"
103,"NCT00646022","Natural History of Familial Carcinoid Tumor",,"Recruiting","No Results Available","Carcinoid","Drug: [18F]-DOPA","Study the natural history of familial carcinoid tumors|Compare the sensitivity and specificity of various imaging modalities: computed tomography (CT) with IV contrast and oral Volumen, 18F-DOPA PET/CT scan, [68Ga]DOTATATE PET/CT scan and endoscopic modalities for diagnosing and following carcinoid ...|Sequester DNA from peripheral blood for genotyping (including sequencing) with the intention of localizing a susceptibility gene/s responsible for the familial occurrence of the disease|Collect tumor specimens for histologic evaluation, culturing of intestinal organoids, and genotyping (including DNA and RNA sequencing)|Screen for occult disease and determine whether early detection affects the natural history of the disease","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"1600","NIH","Observational","Observational Model: Family-Based|Time Perspective: Prospective","080098|08-DK-0098","August 25, 2008",,,"March 28, 2008",,"February 21, 2023","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00646022"
104,"NCT04896684","Chronic Intestinal Pathologies Analytical Cohort at TouLouse","CAPITOL","Recruiting","No Results Available","Inflammatory Bowel Diseases|Colon Cancer","Biological: blood and intestinal biopsy sampling","Biological collection associated with clinical data|Identify new potential therapeutic molecules|Optimize treatment success rates for IBD","University Hospital, Toulouse","All","18 Years to 99 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC31/21/0038","April 29, 2021","January 3, 2023","April 12, 2023","May 21, 2021",,"November 16, 2022","Rangueil University Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04896684"
105,"NCT05432518","GBM Personalized Trial",,"Not yet recruiting","No Results Available","Glioblastoma|Recurrent Disease|Recurrent Glioblastoma","Drug: Afatinib|Drug: Dasatinib|Drug: Palbociclib|Drug: Everolimus|Drug: Olaparib","Success rate of personalized GBM treatment based on molecular characterization of recurrent tumor|Overall survival (OS)|Progression free survival (PFS)|Quality of Life (QoL) EORTC QLQ-C30|Quality of Life (QoL) EORTC QLQ BN-20","AHS Cancer Control Alberta","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBM-2022","June 1, 2023","December 1, 2027","December 1, 2027","June 27, 2022",,"February 2, 2023","Tom Baker Cancer Centre, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT05432518"
106,"NCT05518110","PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer","PaTcH","Not yet recruiting","No Results Available","Pancreatic Cancer","Drug: Trametinib|Drug: Hydroxychloroquine","Patients free of disease progression|Tumour Response Rate|Duration of Response|Overall Survival|Safety and tolerability","Cancer Trials Ireland|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTRIAL-IE 20-27|2021-006276-16","January 31, 2023","July 15, 2024","April 15, 2025","August 26, 2022",,"November 25, 2022","Mater Misericordiae University Hospital, Dublin, Ireland|St Vincent's University Hospital, Dublin, Ireland",,"https://ClinicalTrials.gov/show/NCT05518110"
107,"NCT05412706","Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy","Bohème","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Niraparib","Progression-Free Survival 1|Progression-Free Survival (2) after re-introduction of first-line treatment combination|Overall Survival|Objective Response Rate|Incidence of Treatment-Emergent Adverse Events","Ospedale Policlinico San Martino|CRO ""Centro Clinical Trials"" IRCCS Ospedale Policlinico San Martino|Laboratory Molecular Oncology Candiolo Cancer Institute IRCCS - Candiolo (Torino)","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Bohème","September 1, 2022","September 1, 2027","September 1, 2028","June 9, 2022",,"June 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05412706"
108,"NCT05473923","PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas",,"Recruiting","No Results Available","Recurrent High Grade Glioma","Drug: Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.","The percentage of patients who accomplish the recommended regimen for at least 1 course.|Incidence of Treatment-Emergent Adverse Events (AEs)|Ratio of 6 months overall survival (OS)|Ratio of 12months overall survival (OS)|Progression-free survival (PFS)|Overall survival (OS)","Beijing Tiantan Hospital|Beijing GeneX Health Technology Co., Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KY2022-069-02","August 12, 2022","August 10, 2024","December 31, 2024","July 26, 2022",,"February 15, 2023","Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT05473923"
109,"NCT03146962","High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies",,"Recruiting","No Results Available","Colorectal Cancer|Pancreatic Cancer|Lung Cancer","Drug: Vitamin C","Change in antitumor activity measured by pathologic response based on tumor regression grading in cohort A patients.|3-month disease control rate (DCR) will be evaluated using RECIST v 1.1 in cohort B patients.|Maximal tolerated dose of high dose vitamin C in combination with Y90 radioembolization|Progression-free survival (PFS)|Objective response rate (ORR)|Assessment of pharmacokinetics of high dose vitamin C plasma levels concentrations|Safety of high dose vitamin C administration using CTCAE 4.03.","Weill Medical College of Cornell University|Stand Up To Cancer","All","18 Years and older   (Adult, Older Adult)","Phase 2","78","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1610017688","March 29, 2017","June 2023","June 2023","May 10, 2017",,"October 4, 2022","New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03146962"
110,"NCT05537844","Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma","BriTROC-2","Recruiting","No Results Available","Ovarian Cancer|High Grade Serous Carcinoma|Carcinosarcoma, Ovarian|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|BRCA1 Mutation|BRCA2 Mutation",,"Tumour Biopsies (to be collected from 250 patients)|Whole Blood Samples for germline DNA isolation|Plasma Blood Samples (to be collected for storage for future analyses)|Ascites/Peritoneal Washings (where possible from diagnosis and relapse)","Liz-Anne Lewsley|Ovarian Cancer Action|Cancer Research UK, Glasgow","Female","16 Years and older   (Child, Adult, Older Adult)",,"250","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","BriTROC2-2019","October 27, 2021","October 27, 2024","April 27, 2025","September 13, 2022",,"September 23, 2022","Bristol Haematology & Oncology Centre, Bristol, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College London Hospital, London, United Kingdom|Royal Marsden Hospital NHS Trust, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|St Mary's Hospital, Manchester, United Kingdom|The Christie Hospital NHS Trust, Manchester, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05537844"
111,"NCT04531696","UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research","UPTIDER","Recruiting","No Results Available","Breast Cancer|Hereditary Diseases","Procedure: Blood draw|Procedure: Post-mortem tissue collection","Percentage of patients consenting to participate in the pilot phase|Median time elapsed between moment of death and start of the autopsy|Median time elapsed between collection of first and last sample|Percentage of metastatic organs sampled|Percentage of samples with sufficient quality of DNA extracted|Percentage of samples with sufficient quality of RNA extracted|Concordance between TILs and clinical response to treatment|Rate of T cell exhaustion|Number of mutations in each tumor lesion|Type of mutations in each tumor lesion|Percentage of Tumour Infiltrating Lymphocytes (TILs)","Universitaire Ziekenhuizen KU Leuven|KU Leuven|Universiteit Antwerpen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","S64410","November 30, 2020","September 2035","September 2035","August 28, 2020",,"December 5, 2022","UZ Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT04531696"
112,"NCT04526587","Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors",,"Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8","Other: Cytology Specimen Collection Procedure|Other: Diagnostic Laboratory Biomarker Analysis|Other: Medical Chart Review","Collection of clinical characteristics|Overall survival on ciclib|Progression-free survival on ciclib|Progression-free survival on subsequent therapies|Site of the metastatic disease and time to progression|Incidence of treatment related toxicities|Genetic variance of genes associated with ciclib metabolism|Quantitative biomarker expressions|Development of patient-derived models from resistant disease|Socio-economic features related to the use of ciclibs|Clinical course of CDK4/6 inhibitor treated patients in the ""real-world"" setting","Roswell Park Cancer Institute","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","I 571719|NCI-2020-05682","July 3, 2020","July 3, 2025","July 3, 2025","August 26, 2020",,"May 9, 2022","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT04526587"
113,"NCT02756130","Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",,"Withdrawn","No Results Available","High Grade Fallopian Tube Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma","Drug: Birinapant|Drug: Carboplatin|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Change in percentage of cancer initiating cells|Pharmacodynamic analysis of cellular inhibitor of apoptosis (cIAP) protein|Progression free survival (PFS) assessed using imaging (multiparametric magnetic resonance imaging [MRI] (primary modality of imaging) of computed tomography (CT) and the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria","Jonsson Comprehensive Cancer Center|Alpha Stem Cell Clinic (ASCC)|California Institute for Regenerative Medicine (CIRM)|TetraLogic Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-000746|NCI-2016-00596|GODL001","August 1, 2018","February 1, 2020","February 1, 2021","April 29, 2016",,"July 24, 2020","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02756130"
114,"NCT04821219","Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids",,"Withdrawn","No Results Available","Pancreas Adenocarcinoma","Other: Treatment prediction PDT platform","Rate of the successful establishment of pancreatic patient-derived tumoroids (PDT)|Drug sensitivity and response prediction of chemotherapy agents in PDT|Drug sensitivity and response prediction of radiation therapy in PDT|PDT validation with a comparative analysis of patients' response to neoadjuvant chemotherapy and radiation","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-010804","January 1, 2022","December 31, 2023","December 31, 2023","March 29, 2021",,"February 24, 2022",,,"https://ClinicalTrials.gov/show/NCT04821219"
115,"NCT02910895","Sarcoma Patient Derived Xenografts","SarcomaPDX","Recruiting","No Results Available","Soft Tissue Sarcoma|Xenograft Model|2D/3D Cell Cultures","Other: tumor biopsy","A platform of Patient Derived Xenografts (PDX) of Soft Tissue Sarcomas of patients with sarcomas|The take-rate of fresh human PDX tumour material in nude mice.|A consistent system for further anti-sarcoma therapy (both RT and chemotherapy experiments)|A platform of 2D/3D cell cultures (organoids) of Soft Tissue Sarcomas.|A model for translational research|The passage possibilities of human PDX tumour material by freezing, storing, thawing and re-inoculating in nude mice|Fractionation sensitivity on several STS subtypes in PDX.|To study the passage possibilities of 2D/3D cell cultures by freezing, storing and thawing","The Netherlands Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","N16STS|NL58626.031.16","September 9, 2017","September 2023","September 2023","September 22, 2016",,"October 7, 2022","Netherlands Cancer Institute, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02910895"
116,"NCT05644743","Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma",,"Not yet recruiting","No Results Available","Organoids|Intrahepatic Cholangiocarcinoma","Device: gemcitabine + cisplatin","Consistency of organoids and clinical patient responses to drugs|Construction of drug resistance prediction model","Chengjun Sui,MD|Eastern Hepatobiliary Surgery Hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Other|Time Perspective: Prospective","202240313","January 2023","December 2025","December 2026","December 9, 2022",,"December 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05644743"
117,"NCT05078866","Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients",,"Recruiting","No Results Available","Lynch Syndrome","Biological: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|Biological: MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|Other: Questionnaire Administration","Rates of grade 2/3 adverse events and symptom reactivity following vaccination|Rate of immunogenicity following vaccination|Changes in T cell immune profile and T cell receptor (TCR) repertoire in the peripheral blood|Changes in TCR repertoire within histologically normal colorectal mucosal|Changes in the gene expression profile and TCR repertoire of tumor infiltrating lymphocytes (TIL) within colorectal adenomas|T cell cytotoxicity against matched colorectal adenoma organoids|Percentage change in the number of colorectal adenomas, advanced neoplasia, and/or carcinomas|Rate of Lynch syndrome-related carcinomas|Change in cell free deoxyribonucleic acid (cfDNA) detectability and mutation profile in the peripheral blood|Immune response to Nous-209","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","45","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NCI-2021-10799|2022-0065|MDA21-06-01|P30CA016672|UG1CA242609","September 19, 2022","July 31, 2025","July 31, 2025","October 15, 2021",,"November 23, 2022","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Puerto Rico, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT05078866"
118,"NCT04587128","Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC",,"Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: Cetuximab|Drug: Irinotecan","Cohort A Objective Response Rate (ORR)|Cohort B Progression Free Survival (PFS)|Cohort A Progression Free Survival (PFS)|Cohort B Objective Response Rate (ORR)|Type and Severity of Toxicities|Rate of Retreatment with EGFRi|Overall Survival (OS)","University of Wisconsin, Madison|Doris Duke Charitable Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW20038|A534260|SMPH/MEDICINE/HEM-ONC|Protocol Version 3/8/2021|2020-0714|NCI-2020-06543","October 19, 2020","October 2025","October 2025","October 14, 2020",,"September 15, 2022","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04587128"
119,"NCT05727020","Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma","VAPOR","Recruiting","No Results Available","PDAC - Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer","Diagnostic Test: Breath test|Diagnostic Test: Collection of matched samples of breath, biofluids and pancreatic tissue","Levels of VOCs present in breath of subjects with PDAC and controls|Levels of volatile metabolites present in headspace of the urine of subjects with PDAC and controls|Characterisation of bacterial species in saliva samples, pancreatic tissue samples and duodenal aspirate samples of subjects with PDAC compared to controls|Levels of VOCs produced by the bacteria isolated from saliva samples, pancreatic tissue samples and duodenal aspirate samples of subjects with PDAC","Imperial College London|Pancreatic Cancer UK|Imperial College Healthcare NHS Trust|Royal Free Hospital NHS Foundation Trust|Liverpool University Hospitals NHS Foundation Trust|The Leeds Teaching Hospitals NHS Trust|Sheffield Teaching Hospitals NHS Foundation Trust|University Hospital Southampton NHS Foundation Trust|Royal Surrey County Hospital NHS Foundation Trust|University Hospital Birmingham NHS Foundation Trust|Manchester University NHS Foundation Trust|Newcastle-upon-Tyne Hospitals NHS Trust","All","18 Years and older   (Adult, Older Adult)",,"963","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","22HH7787","December 15, 2022","July 2024","January 2025","February 14, 2023",,"February 14, 2023","Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05727020"
120,"NCT03307538","Stereotactic Body Radiation Therapy for Unresectable Perihilar Cholangiocarcinoma","STRONG","Completed","No Results Available","Klatskin Tumor","Radiation: Stereotactic body radiation therapy","Acute toxicity|Quality of life|Local progression|Progression free survival|Overall survival|Cellular radiosensitivity","Erasmus Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL 60588.078.17","November 6, 2017","March 30, 2020","June 30, 2020","October 11, 2017",,"January 26, 2021","Erasmus MC, Rotterdam, Zuid Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03307538"
121,"NCT04622423","Advanced Therapies for Liver Metastases","LiMeT","Recruiting","No Results Available","Pancreatic Ductal Adenocarcinoma (PDAC)|Colorectal Cancer (CRC)|Liver Metastasis",,"Definition of tumor mutational burden, epigenetic and gene expression profile of the CRC and PDAC metastatic liver at bulk and at single cell level|Characterization of the immune landscapes of CRC and, if possible, PDAC liver MTS by high dimensional flow cytometry|Histological validation of the molecular results obtained in 1. and 2.|Definition of the antigenic landscape and TCR repertoire of CRC and PDAC liver MTS|Evaluation of the molecular and cellular composition of CRC and, if possible, PDAC liver MTS by spatial transcriptomics technologies (NICHE-seq and Visium)|Collection of clinical follow-up data|Collection and biobanking of follow-up samples from patients with CRC and metachronous PDAC MTS to the liver|Biobanking of biospecimens collected from CRC and PDAC patients and from healthy donors","IRCCS San Raffaele|Università Vita-Salute San Raffaele","All","18 Years and older   (Adult, Older Adult)",,"475","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LiMeT|22737","November 6, 2019","June 30, 2026","June 30, 2026","November 10, 2020",,"August 10, 2022","IRCCS San Raffaele, Milan, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT04622423/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT04622423"
122,"NCT04951115","A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer",,"Recruiting","No Results Available","Small-cell Lung Cancer","Drug: Carboplatin|Drug: Cisplatin|Drug: Etoposide|Drug: Durvalumab|Radiation: Stereotactic Body Radiotherapy","Number of toxicities Grade 3 or above related to therapy|Efficacy of multi-site, non-ablative radiation to standard systemic therapy for patients with extensive-stage small cell lung, as measured by a change in disease response|Objective response rate, determined by disease response rate defined by the RECIST 1.1 criteria|Overall survival, defined as the time from first study treatment to the time of death from any cause|Pattern of disease progression, defined by the progression in radiated lesions vs. non-radiated lesions and the rates of new lesions as determined by RECIST 1.1","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-08022492","July 12, 2021","October 1, 2024","July 1, 2025","July 6, 2021",,"August 1, 2022","New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|New York-Presbyterian Queens, Flushing, New York, United States|Weill Cornell Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04951115"
123,"NCT04868396","Patient-derived Glioma Stem Cell Organoids",,"Active, not recruiting","No Results Available","Glioblastoma","Procedure: Tumor biopsy","Organoid cultures|Long term culturing and biobanking conditions for GM organoids|Intra-organoid heterogeneity reflects intra-tumoral genetic and epigenetic heterogeneity|GM organoid model|Define oncogenic drivers|Organoid platform|ctDNA","Maastricht Radiation Oncology","All","18 Years and older   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Glioma stem cell organoids","April 10, 2021","September 1, 2022","January 1, 2023","April 30, 2021",,"August 24, 2022","Maastricht UMC+, Maastricht, Limburg, Netherlands|Maastricht Radiation Oncology, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT04868396"
124,"NCT05634694","Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients",,"Recruiting","No Results Available","Cholangiocarcinoma","Other: No interventions.","Progression-free survival status of cholangiocarcinoma patients after radical resection|Drug sensitivity of patient-derived tumor organoids","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","All","18 Years to 75 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SYSKY-2022-168-01","November 30, 2022","December 1, 2023","December 1, 2024","December 2, 2022",,"December 2, 2022","Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05634694"
125,"NCT04072445","Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer",,"Active, not recruiting","Has Results","Advanced Bile Duct Carcinoma|Advanced Gallbladder Carcinoma|Refractory Bile Duct Carcinoma|Refractory Gallbladder Carcinoma|Stage III Distal Bile Duct Cancer AJCC v8|Stage III Gallbladder Cancer AJCC v8|Stage III Intrahepatic Bile Duct Cancer AJCC v8|Stage IIIA Distal Bile Duct Cancer AJCC v8|Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8|Stage IIIB Distal Bile Duct Cancer AJCC v8|Stage IIIB Gallbladder Cancer AJCC v8|Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8|Stage IV Distal Bile Duct Cancer AJCC v8|Stage IV Gallbladder Cancer AJCC v8|Stage IV Intrahepatic Bile Duct Cancer AJCC v8|Stage IVA Gallbladder Cancer AJCC v8|Stage IVB Gallbladder Cancer AJCC v8","Drug: Irinotecan|Drug: Irinotecan Hydrochloride|Drug: Trifluridine and Tipiracil Hydrochloride","Progression-free Survival (PFS)|Overall Response Rate (ORR)|Disease Control Rate (DCR)|PFS|Overall Survival (OS)|Number of Participants With Adverse Events","Mayo Clinic|National Cancer Institute (NCI)|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1941|NCI-2019-05653","October 18, 2019","August 13, 2021","May 15, 2023","August 28, 2019","September 22, 2022","January 9, 2023","Mayo Clinic, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04072445/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04072445"
126,"NCT05772767","Modulation of Ciliogenesis in Glioma Stem Cells","RF2019-1236878","Recruiting","No Results Available","Glioblastoma|Glioma, Malignant","Other: Biological sample collection|Other: Dissecting ciliogenesis players|Diagnostic Test: Validating ciliogenesis players","Biological","Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Istituto Superiore di Sanità|Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","3782","February 15, 2021","February 28, 2024","February 28, 2024","March 16, 2023",,"March 16, 2023","Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT05772767"
127,"NCT04478877","Establishment and Characterization of Meningioma Patient-derived Organoids",,"Recruiting","No Results Available","Meningioma",,"Whole exome sequencing data|Immunostaining","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Other|Time Perspective: Prospective","GWMO01","May 23, 2020","December 31, 2023","December 31, 2023","July 21, 2020",,"March 9, 2022","Department of Surgery, The Chinese University of Hong Kong, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04478877"
128,"NCT05411107","Oral Iloprost for the Prevention of Lung Cancer In Former Smokers",,"Not yet recruiting","No Results Available","Bronchial Epithelial Dysplasia|Chronic Obstructive Pulmonary Disease|Lung Carcinoma|Stage I Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Tobacco-Related Carcinoma","Procedure: Biospecimen Collection|Procedure: Bronchial Brush Biopsy|Procedure: Bronchoscopy|Drug: Iloprost|Drug: Placebo Administration|Other: Questionnaire Administration","Change in numerical grade of the worst (highest grade on the WHO scale) dysplastic lesion per subject on bronchoscopy|Change in the average WHO score of all biopsy sites with a baseline score of 4 or greater|Incidence of adverse events with oral iloprost","National Cancer Institute (NCI)","All","50 Years and older   (Adult, Older Adult)","Phase 2","80","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","NCI-2022-04698|NCI21-08-01|NWU21-08-01|P30CA060553|UG1CA242643","December 1, 2023","December 1, 2026","December 1, 2026","June 9, 2022",,"March 14, 2023","Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States|University of Colorado, Denver, Colorado, United States|Northwestern University, Chicago, Illinois, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT05411107"
129,"NCT03764553","Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer","LyRICX","Recruiting","No Results Available","Esophageal Cancer","Drug: Liposomal Irinotecan|Drug: Carboplatin|Drug: Capecitabine|Drug: Oxaliplatin|Drug: 5-fluorouracil|Drug: Leucovorin","Progression free survival|Number of participants with treatment-related Neurotoxicity|Overall survival|response rate|adverse events|Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ C30))|percentage subsequent treatment lines|the reasons for forgoing subsequent treatment","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Servier","All","18 Years and older   (Adult, Older Adult)","Phase 2","310","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018_256","May 1, 2019","August 1, 2024","August 1, 2024","December 5, 2018",,"December 16, 2022","VieCuri, Venlo, Limburg, Netherlands|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Meander MC, Amersfoort, Netherlands|Academic Medical Center, Medical Oncology, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Hagaziekenhuis, Den Haag, Netherlands|Catherina Ziekenhuis, Eindhoven, Netherlands|Admiraal de Ruijter Ziekenhuis, Goes, Netherlands|Treant zorggroep, Hoogeveen, Netherlands|VieCurie, Roermond, Netherlands|Laurentius Ziekenhuis, Roermond, Netherlands|Bravis ziekenhuis locatie Roosendaal, Roosendaal, Netherlands|UMCU, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03764553"
130,"NCT04753996","Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients",,"Recruiting","No Results Available","Primary Sclerosing Cholangitis|PSC|Cholangiocarcinoma",,"Number of participants in study.|Number of samples (per type)|Number of clinical phenotypes and/or observations.","Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 85 Years   (Adult, Older Adult)",,"300","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20-012867","March 8, 2021","January 1, 2025","January 1, 2030","February 15, 2021",,"January 10, 2023","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04753996"
131,"NCT05532397","Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma",,"Not yet recruiting","No Results Available","Glioma, Astrocytic","Drug: QPOP category 1|Drug: QPOP category 2","Six-month progression-free survival (PFS 6)|Radiological response at follow up MRI|Twelve-month overall survival (OS12)|Number of participant with treatment related haematological and non-haematological toxicities","National University Hospital, Singapore|National University of Singapore","All","21 Years to 99 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QP/25/05/21","November 2022","December 2024","December 2025","September 8, 2022",,"September 8, 2022","Department of Hematology-Oncology, National University Hospital, Singapore, Singapore|Ng Teng Fong General Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT05532397"
132,"NCT04986748","Using QPOP to Predict Treatment for Sarcomas and Melanomas",,"Recruiting","No Results Available","Sarcoma|Melanoma",,"Percentage of patients with successful model generation for each tumour subtype.|Rates of radiological response from QPOP-directed treatment regimens.|Survival outcomes from QPOP-directed treatment regimens.","National Cancer Centre, Singapore","All","21 Years to 99 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Q-SAM","September 8, 2020","October 31, 2028","December 31, 2028","August 3, 2021",,"September 28, 2022","National Cancer Centre Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04986748"
133,"NCT02695459","Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin",,"Active, not recruiting","No Results Available","Neuroendocrine Carcinomas","Drug: cisplatinum and everolimus","disease control rate|time to relapse|overall survival|Effect on the markers chromogranin A (CgA) and neuron-specific enolase (NSE);|Safety of everolimus in combination with cisplatin (AEs according to CTCAE v4.0)","The Netherlands Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14NEC","March 30, 2016","April 2021","August 2021","March 1, 2016",,"April 20, 2021","NKI-AVL, Amsterdam, Netherlands|UMCG, Groningen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02695459"
134,"NCT02869802","Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis","PanGen","Recruiting","No Results Available","Cancer|Pancreatic Cancer","Procedure: Tumour Biopsy|Other: Serial Collection of Plasma and Serum Samples","Number of days between biopsy and return of comprehensive genomic results.|Response Rate|Disease Control Rate|Duration of Response|Progression-Free Survival|Overall Survival","British Columbia Cancer Agency|Terry Fox Research Institute|BC Cancer Foundation|Pancreas Centre BC","All","18 Years and older   (Adult, Older Adult)",,"190","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H20-02375|H16-00291","October 6, 2016","December 2023","December 2024","August 17, 2016",,"June 22, 2022","Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer - Vancouver, Vancouver, British Columbia, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02869802"
135,"NCT05630794","Testing ONC201 to Prevent Colorectal Cancer",,"Not yet recruiting","No Results Available","Colorectal Adenomatous Polyp|Colorectal Carcinoma|Familial Adenomatous Polyposis|Multiple Adenomatous Polyps","Procedure: Biopsy|Procedure: Biospecimen Collection|Procedure: Colonoscopy|Drug: Dordaviprone|Other: Questionnaire Administration|Procedure: Sigmoidoscopy","Mean change in human adenoma tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in polyps induced by ONC201|Mean change in normal human mucosa TRAIL expression induced by ONC201|Proportion and severity of treatment emergent adverse events","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NCI-2022-09737|Pending17|UMI22-09-02|P30CA046592|UG1CA242632","May 13, 2023","February 1, 2025","February 1, 2025","November 30, 2022",,"January 4, 2023","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT05630794"
136,"NCT03358628","Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osteosarcoma",,"Not yet recruiting","No Results Available","Osteosarcoma","Other: Molecular Profiling & In Vivo drug testing in PDX","Measure of drug sensitive PDX to a panel of drugs as a predictor of clinical response in matched host","Peking University People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017PHB278-01","February 1, 2018","January 31, 2020","January 31, 2025","November 30, 2017",,"November 30, 2017",,,"https://ClinicalTrials.gov/show/NCT03358628"
137,"NCT02718235","Prospective, Multicenter HCCIS Evaluation Study","HCCIS","Unknown status","No Results Available","Hepatocellular Carcinoma","Other: Overall survival","The HCC immune score (HCCIS) is a survival prognosticator of patients after liver resection for HCC|The HCC immune score (HCCIS) to prognosticate disease free survival of patients after liver resection for HCC","University of Regensburg|Else Kröner Fresenius Foundation","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HCCIS16","June 2016","June 2021","June 2021","March 24, 2016",,"March 24, 2016",,,"https://ClinicalTrials.gov/show/NCT02718235"
138,"NCT04219137","Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study","MOCHA","Recruiting","No Results Available","Esophagogastric Adenocarcinoma","Genetic: Molecular Profiling","GEA sequencing data and molecular profiling|Establishment of GEA treatment algorithms|Establishment of personalized GEA treatment protocols|GEA BioBank repository|GEA PDO and PDX models","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-5663","November 14, 2019","November 2021","November 2021","January 6, 2020",,"April 29, 2021","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04219137"
139,"NCT04045730","The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.",,"Withdrawn","No Results Available","Pancreas Adenocarcinoma","Drug: Gemcitabine","Progression Free Survival (PFS) rate|Overall Survival Rate median|Overall Response Rate (ORR)|Number of patients with treatment related adverse events as assessed by CTCAE v5.0","Yale University","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000024450","November 15, 2019","December 31, 2019","July 31, 2021","August 5, 2019",,"January 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04045730"
